Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06656325 · ClinicalTrials.gov registry record · NA
An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis
A NA study of Periodontal Diseases and Periodontitis, sponsored by Erchonia Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT06656325: Recruiting NA study of Periodontal Diseases and Periodontitis, sponsored by Erchonia Corporation.
NCT06656325 is a NA study of Periodontal Diseases and Periodontitis that is actively recruiting participants, run by Erchonia Corporation. The registered enrollment target is 70 participants, below the 157-participant average among 15 other Periodontal Diseases trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06656325, a NA study of Periodontal Diseases and Periodontitis, is actively recruiting participants, sponsored by Erchonia Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.
Primary Outcome
The Clinical Attachment Loss (CAL) from baseline to endpoint (8 months) measurement is calculated for each subject. Individual subject success is defined as a 2mm or greater change in CAL at the primary tooth assessment site across the evaluation period. A negative (-) change indicates a reduction in periodontitis and is positive for individual subject success. A lower CAL score from baseline to study endpoint represents a better outcome, whereas a higher score from baseline to study endpoint re
Conditions Studied
Interventions
- DEVICE Erchonia® FX405
- DEVICE Placebo Laser
Study Locations (2)
California
- 805 Dentistry - Thousand Oaks
Massachusetts
- Acton Dental Associates - Acton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2027-02-01 |
| Phase | NA |
What NCT06656325 shows while recruiting
NCT06656325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 157-participant average among 15 other Periodontal Diseases trials with a reported enrollment target (55% lower).
The record links to 3 conditions, with Periodontal Diseases appearing as the primary indexed condition, and to 2 interventions - of which Erchonia® FX405 is the first listed.
NCT06656325 reports a single indexed study location in California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06656325 about?
NCT06656325 is a clinical study titled "An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis". The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease...
What is the current status of trial NCT06656325?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-01-01. Estimated completion is 2027-02-01.
What conditions does trial NCT06656325 study?
This clinical trial studies the following conditions: Periodontal Diseases, Periodontitis, Gum Disease.
What interventions are being tested in trial NCT06656325?
The interventions under investigation include: Erchonia® FX405 (DEVICE), Placebo Laser (DEVICE).
Who is sponsoring clinical trial NCT06656325?
This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06656325 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Periodontal Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06656325's enrollment target sits among peer trials
70 9th of 15 higher than 7 of 15 other Periodontal Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Periodontal Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel Dental Gel as an Adjunct to Scaling and Root Planing
RECRUITING · NA
-
Oral Health Intervention in Adult Primary Care
RECRUITING · NA
-
F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)
RECRUITING · NA
-
Microsurgery and Periodontal Healing
RECRUITING · NA
-
Addition of Dehydrated Human Amnion-Chorion Membrane During Scaling and Root Planing
ACTIVE NOT RECRUITING · NA
-
Application of L-PRF in Periodontal Surgery
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI